1. Diagnostic value of using a combination of nucleic acid and specific antibody tests for SARS-CoV-2 in coronavirus disease 2019
- Author
-
Suping Hu, Tao Wang, Yang Zhao, Shaolin Zeng, Kaochang Zhao, Xuhong Ding, Li Ai, Zhishui Zheng, and Hanxiang Nie
- Subjects
Adult ,0301 basic medicine ,Coronavirus disease 2019 (COVID-19) ,Epidemiology ,viruses ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Review ,Disease ,Antibodies, Viral ,Diagnosis, Differential ,Young Adult ,03 medical and health sciences ,COVID-19 Testing ,0302 clinical medicine ,Pneumonia, Bacterial ,medicine ,Humans ,030212 general & internal medicine ,skin and connective tissue diseases ,Lung ,Antibody ,medicine.diagnostic_test ,biology ,SARS-CoV-2 ,business.industry ,fungi ,COVID-19 ,virus diseases ,Nucleic acid test ,Virology ,Anti-Bacterial Agents ,COVID-19 Drug Treatment ,nucleic acid ,body regions ,Specific antibody ,Treatment Outcome ,030104 developmental biology ,Infectious Diseases ,Nucleic acid ,biology.protein ,RNA, Viral ,Female ,Differential diagnosis ,business - Abstract
Coronavirus disease 2019 (COVID-19) is a newly emerged disease with various clinical manifestations and imaging features. The diagnosis of COVID-19 depends on a positive nucleic acid amplification test by real-time reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the clinical manifestations and imaging features of COVID-19 are non-specific, and nucleic acid test for SARS-CoV-2 can have false-negative results. It is presently believed that detection of specific antibodies to SARS-CoV-2 is an effective screening and diagnostic indicator for SARS-CoV-2 infection. Thus, a combination of nucleic acid and specific antibody tests for SARS-CoV-2 will be more effective to diagnose COVID-19, especially to exclude suspected cases.
- Published
- 2021